Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Eribulin · Halaven

Small molecule · Inhibitor of tubulin · developed by Eisai

Approved FDA, Nov 2010

3 Registered trials

What is Eribulin?

Eribulin is an analogue of halichondrin B that binds the vinca domain of tubulin, inhibiting tubulin polymerization and microtubule assembly. This blocks mitotic spindle formation and causes G2/M cell cycle arrest. It is studied in HER2-positive and metastatic breast cancer, HER2-positive gastric cancer, HER2-positive solid tumors and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Halaven
Drug type: Small molecule
Targets: tubulin
Mechanism: Inhibitor of tubulin
Pathways: microtubule assembly, mitotic spindle assembly, G2/M cell cycle arrest
Therapy area: Oncology
Developer: Eisai Inc
In trials of: ALXO, AZN, ELVN
FDA status: Approved as Halaven (November 15, 2010), NDA201532 · FDA label

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03734029	Phase 3	Breast Cancer	Completed	AZN
NCT07007559	Phase 2	Breast Cancer, Metastatic	Recruiting	ALXO
NCT06328738	Phase 1	HER2-positive Breast Cancer	Active not recruiting	ELVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast Cancer, MetastaticColorectal CancerHER2 AmplificationHER2 Positive Solid TumorsHER2-positive Breast CancerHER2-positive Gastric CancerBreast Cancer

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z